Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Methods This was a 6-month double-blind, placebo-controlled, randomised, cross-over trial followed by a 6-month open-label phase.

Cardiac magnetic resonance imaging, echocardiography, and cardiopulmonary exercise testing were performed at baseline, 12 weeks, 26 weeks, and the end of the open phase (12 months).

Who Took Part

PubMed indexes the participants as young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, open-label, placebo-controlled and crossover.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the participants and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

Cardiac magnetic resonance imaging, echocardiography, and cardiopulmonary exercise testing were performed at baseline, 12 weeks, 26 weeks, and the end of the open phase (12 months).

PubMed files the paper under topics including Exercise, Growth Hormone, Heart, Human Growth Hormone, Magnetic Resonance Imaging and Recombinant Proteins.

Author keywords: adult-onset growth hormone deficiency, cardiac function, cardiac magnetic resonance imaging, cardiac structure, exercise capacity and hypopituitarism.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2017 (The Journal of international medical research), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.